Results 11 to 20 of about 104,861 (298)
Hereditary Cancer in Clinical Practice, 2015 بوليميرازات بولي (ADP - ريبوز)، التي يتم اختصارها باسم PARPs، هي مجموعة من البروتينات المألوفة التي تلعب دورًا مركزيًا في إصلاح الحمض النووي باستخدام مسار إصلاح استئصال القاعدة (BER). هناك حوالي 17 بروتينًا في هذه العائلة منها PARPs النووية الأولية هي PARP -1 و PARP -2 و PARP -3 و tankyrases 1 و 2 (PARP -5a و -5b).
Maheen Anwar +2 more
+6 more sources
PARP inhibitors: the race is on [PDF]
British Journal of Cancer, 2016 Since the seminal publications in 2005 that demonstrated the exquisite sensitivity of BRCA1 and BRCA2 (BRCA1/2) mutant cell lines and xenografts to poly(ADP-ribose) polymerase (PARP) inhibition (Bryant et al, 2005; Farmer et al, 2005), the race has been on to exploit single-agent PARP inhibitors for clinical use through the concept of tumour-specific ...
Brown, Jessica S +2 more
openaire +2 more sources
Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods [PDF]
PeerJ, 2020 Background Research has shown that Poly-ADP-ribose polymerases 1 (PARP-1) is a potential therapeutic target in the clinical treatment of breast cancer.
Hongye Hu +3 more
doaj +2 more sources
Molecular Oncology, 2022 Poly[ADP‐ribose] polymerase (PARP) inhibitors can block DNA single‐strand damage repair and subsequently increase double‐stranded breaks (DSBs) by reducing the activity of the PARP1 protease and by preventing the PARP1 protein from dissociating from ...
Xiang Cheng +4 more
doaj +1 more source
A clinical case of repeat use of PARP inhibitors in a patient with mBRCA-associated ovarian cancer
Сибирский онкологический журнал, 2022 Backgraound. High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. The prevalence of BRCA1/2 germline mutations is the highest in HGSOC.
A. B. Villert +5 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment.
Priya Bisht +4 more
doaj +1 more source
Annals of Internal Medicine: Clinical Cases, 2023 Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of several types of cancers. We report a case of an 80-year-old Japanese woman who developed drug-induced interstitial lung disease (ILD) during treatment with PARP inhibitors (
Hiroshi Sugimoto +5 more
doaj +1 more source
PARP Inhibitors in Prostate Cancer [PDF]
Anticancer Research, 2021 Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in ...
Kabir, Grewal +2 more
openaire +2 more sources
Frontiers in Pharmacology, 2023 Background: Since its discovery, poly (ADP-ribose) polymerase 1 (PARP-1) has been extensively studied due to its regulatory role in numerous biologically crucial pathways.
Wen-Hao Li +6 more
doaj +1 more source
Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
Frontiers in Oncology, 2021 Poly (ADP-ribose) polymerase (PARP) inhibitors constitute an important treatment option for ovarian cancer nowadays. The magnitude of benefit from PARP inhibitors is influenced by the homologous recombination status, with greater benefit observed in ...
Renata Colombo Bonadio +3 more
doaj +1 more source